We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 30, 2020

AXL Is a Predictor of Poor Survival and of Resistance to Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer

European Journal of Cancer

 

Additional Info

European Journal of Cancer
AXL Is a Predictor of Poor Survival and of Resistance to Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
Eur. J. Cancer 2020 Oct 01;138(xx)1-10, C Cardone, B Blauensteiner, V Moreno-Viedma, G Martini, V Simeon, PP Vitiello, D Ciardiello, V Belli, N Matrone, T Troiani, F Morgillo, F Zito Marino, M Dentice, A Nappi, A Boccaccino, C Antoniotti, C Cremolini, F Pietrantonio, GW Prager, N Normanno, E Maiello, G Argiles, E Elez, G Signoriello, R Franco, A Falcone, J Tabernero, M Sibilia, F Ciardiello, E Martinelli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading